US protection ending in 2029: Injuries
As of the edition of 20 October 2026, 11 drugs have US protection that ends in 2029 in injuries; 7 of them have at least one company on route B because of it.
Sources: FDA Orange Book and Purple Book, other approval registers.
11 drugs
| Drug | US protection | Status | Holder | Target | Route B rows |
|---|---|---|---|---|---|
| Atezolizumab | Ends 2029 (orphan exclusivity) | Marketed | Roche | CD274 | 1 |
| Budesonide | Ends 2029 (exclusivity) | Marketed | NR3C1 | 5 | |
| Dapagliflozin | Ends 2029 (patent) | Marketed | AstraZeneca | SLC5A2 | 2 |
| Edaravone | Ends 2029 (exclusivity) | Marketed | Shionogi | 0 | |
| Flurpiridaz | Ends 2029 (exclusivity) | Marketed | GE Healthcare | 0 | |
| Lapatinib | Ends 2029 (patent) | Marketed | Novartis | EGFR | 2 |
| Nitric oxide | Ends 2029 (patent) | Marketed | Byk-Mallinckrodt CIL | GUCY1B1, GUCY1B2 | 4 |
| Oxymorphone | Ends 2029 (patent) | Marketed | Endo | OPRD1, OPRK1, OPRM1 | 0 |
| Phenobarbital | Ends 2029 (exclusivity) | Marketed | SUN Pharmaceutical Industries | 0 | |
| Ruxolitinib | Ends 2029 (exclusivity) | Marketed | JAK1, JAK2 | 4 | |
| Trazodone | Ends 2029 (patent) | Marketed | Pragma Pharmaceuticals | HTR2A, HTR2C | 1 |
Listed by name. A route B row is one company at one target; for a drug with one target that is the number of companies. US protection is the US only, and it is not the date generics or biosimilars can enter.
Which companies are on route B in 2029 in injuries
In the product7 of these 11 drugs have at least one company on route B. Which companies, and their scores, are in the product.
Get this list with the companies, scores and sources as a fileRequest access. Nothing is shown until you do.